排序方式: 共有1条查询结果,搜索用时 15 毫秒
1
1.
Northcott PA Shih DJ Peacock J Garzia L Morrissy AS Zichner T Stütz AM Korshunov A Reimand J Schumacher SE Beroukhim R Ellison DW Marshall CR Lionel AC Mack S Dubuc A Yao Y Ramaswamy V Luu B Rolider A Cavalli FM Wang X Remke M Wu X Chiu RY Chu A Chuah E Corbett RD Hoad GR Jackman SD Li Y Lo A Mungall KL Nip KM Qian JQ Raymond AG Thiessen NT Varhol RJ Birol I Moore RA Mungall AJ Holt R Kawauchi D Roussel MF Kool M Jones DT Witt H Fernandez-L A Kenney AM Wechsler-Reya RJ Dirks P Aviv T 《Nature》2012,488(7409):49-56
Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive chemotherapy. As medulloblastoma exhibits marked intertumoural heterogeneity, with at least four distinct molecular variants, previous attempts to identify targets for therapy have been underpowered because of small samples sizes. Here we report somatic copy number aberrations (SCNAs) in 1,087 unique medulloblastomas. SCNAs are common in medulloblastoma, and are predominantly subgroup-enriched. The most common region of focal copy number gain is a tandem duplication of SNCAIP, a gene associated with Parkinson's disease, which is exquisitely restricted to Group 4α. Recurrent translocations of PVT1, including PVT1-MYC and PVT1-NDRG1, that arise through chromothripsis are restricted to Group 3. Numerous targetable SCNAs, including recurrent events targeting TGF-β signalling in Group 3, and NF-κB signalling in Group 4, suggest future avenues for rational, targeted therapy. 相似文献
1